US 12,221,489 B2
Antibodies to human B7x for treatment of metastatic cancer
Xingxing Zang, New York, NY (US); and James P. Allison, Houston, TX (US)
Assigned to ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, NY (US); and SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, New York, NY (US)
Filed by ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, NY (US); and SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, New York, NY (US)
Filed on Aug. 27, 2020, as Appl. No. 17/004,331.
Application 15/252,267 is a division of application No. 14/050,512, filed on Oct. 10, 2013, granted, now 9,447,186, issued on Sep. 20, 2016.
Application 17/004,331 is a continuation of application No. 15/252,267, filed on Aug. 31, 2016, abandoned.
Application 14/050,512 is a continuation in part of application No. PCT/US2012/034348, filed on Apr. 20, 2012.
Claims priority of provisional application 61/477,729, filed on Apr. 21, 2011.
Prior Publication US 2020/0392246 A1, Dec. 17, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 49/00 (2006.01); C07K 16/30 (2006.01); G01N 33/50 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/30 (2013.01) [A61K 9/0019 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 49/0008 (2013.01); C07K 16/28 (2013.01); C07K 16/2827 (2013.01); C07K 16/3015 (2013.01); C07K 16/3023 (2013.01); C07K 16/303 (2013.01); C07K 16/3038 (2013.01); C07K 16/3046 (2013.01); C07K 16/3053 (2013.01); C07K 16/3069 (2013.01); G01N 33/5011 (2013.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 13 Claims
 
1. An IgG1 monoclonal antibody or a fragment thereof comprising a means for selectively binding to human B7x amino acid residues 35-148 of SEQ ID NO: 1 with an equilibrium dissociation constant from residues 35-148 of SEQ ID NO: 1 that is less than 50 nM, wherein the IgG1 monoclonal antibody is capable of killing tumor cells through antibody-dependent cellular cytotoxicity.